Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below 50 Day Moving Average of $0.91

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.91 and traded as low as $0.61. Seres Therapeutics shares last traded at $0.62, with a volume of 3,849,237 shares.

Wall Street Analysts Forecast Growth

MCRB has been the topic of a number of recent analyst reports. Oppenheimer decreased their target price on Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, March 6th. Chardan Capital cut their target price on Seres Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 6th.

Seres Therapeutics Stock Down 1.4 %

The stock has a 50 day simple moving average of $0.89 and a 200 day simple moving average of $1.15. The stock has a market cap of $94.73 million, a price-to-earnings ratio of -0.70 and a beta of 2.23.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.08. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.50 million. Equities analysts expect that Seres Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Institutional Trading of Seres Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC purchased a new position in shares of Seres Therapeutics in the 3rd quarter worth about $26,000. Simplicity Solutions LLC bought a new position in shares of Seres Therapeutics in the 3rd quarter worth approximately $27,000. Stifel Financial Corp bought a new position in shares of Seres Therapeutics in the 4th quarter worth approximately $28,000. Wexford Capital LP bought a new position in Seres Therapeutics during the 4th quarter valued at approximately $29,000. Finally, GTS Securities LLC bought a new position in Seres Therapeutics during the 3rd quarter valued at approximately $32,000. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.